TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04531527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butenafine HCl 1% (BAY1896425)
Description: Approximately 60 μl of Butenafine HCl 1% applied twice to the treated irradiated site and to the treated non-irradiated site for a total application of 240 μl of Butenafine HCl 1%.
Study: NCT03177187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5069
Description: 10mg and 40mg plain, beige, film-coated tablets packaged in bottles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5069
Description: 10mg and 40mg plain, beige, film-coated tablets packaged in bottles
Study: NCT02093962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-302 combination with pemetrexed
Description: 400 mg/m2 of TH-302 will be administered by IV infusion over 30 - 60 minutes on Day 1 and Day 8 of a 21-day cycle.~Pemetrexed (500 mg/m2) will be administered as an IV infusion on Day 1 two - four hours after TH-302 administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matched placebo in combination with pemetrexed
Description: Matched placebo will be administered by IV infusion over 30 - 60 minutes on Day 1 and Day 8 of a 21-day cycle.~Pemetrexed (500 mg/m2) will be administered as an IV infusion on Day 1 two - four hours after placebo administration.
Study: NCT04621045

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Physical Activity for The Heart (PATH) intervention
Description: The web-based Physical Activity for The Heart (PATH) intervention leverages openly accessible platforms, such as YouTube, to proffer workout videos that match the participants preferences. Currently, PATH includes over 90 workout videos vetted by a team of experts and curated on the PATH website in 3 controlled levels of intensity (beginner, intermediate, proficient) to foster gradual progression from low to high intensity PA in accordance with the FITT-VP (frequency, intensity, time, type, volume, progression) principle.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Be Active Your Way Booklet
Description: Be Active Your Way booklet was developed by the Centers for Disease Control (CDC) to help individuals integrate PA in their daily lives. It simply encourages individuals to increase their PA gradually and gives them examples of things that they can do.
Study: NCT01956162

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthèse Diabète
Description: The device ensures the discharge of the wound by the excavation of the orthopedic insole facing the wound and the load distribution in the healthy areas.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Device
Description: Standard (e.g.: CHUT, BAROUK, Tera-Diab, Sanital, Teraheel, Aircast boots, Walker Stabil D, etc.), or customized (orthopedic insole, Ransart boot, D.T.A.C.P., etc.) removable off-loading systems
Study: NCT06708247

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Peri-implant Reconstructive Surgery
Description: This intervention involves standard peri-implant reconstructive surgery without the additional step of electrolytic cleaning. The procedure includes mechanical debridement of the implant surface to remove biofilm, followed by bone grafting using autogenous bone harvested from the tuberosity and coverage with a resorbable collagen membrane for bone regeneration and stabilization of the implant.
Study: NCT03177187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide 40 MG
Description: Enzalutamide is presented in 40mg white to off white capsules or tablets. The capsules/tablets are provided in a cardboard wallet incorporating a PVC/PCTFE/aluminium blister which holds 28 soft capsules/tablets. Each carton contains 4 wallets (112 soft capsules/tablets). Or tablets in bottles (120 per bottle).
Study: NCT06708247

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrolytic Cleaning with Peri-implant Reconstructive Surgery
Description: This intervention involves peri-implant reconstructive surgery with an added step of electrolytic cleaning for enhanced implant surface decontamination. The procedure starts with mechanical debridement of the implant surface, followed by the use of an electrolytic cleaning device to remove biofilm and contaminants without damaging the implant surface. This is then followed by bone grafting using autogenous tuberosity bone and coverage with a resorbable collagen membrane to promote bone regeneration and implant stability.
Study: NCT00112151

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Weight training 45-60 minutes 3 times per week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Training
Description: Weight training 45-60 minutes 3 times per week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2.5 gm gel packets applied once daily. Sham adjustments made during the first 12 weeks. Duration is 52 weeks.
Study: NCT06709937

Intervention type: OTHER
Intervention: Prospective multicenter registry of patients with cutaneous metastases from breast carcinoma treated with electrochemotherapy.
Description: electrochemotherapy.
Study: NCT02513914

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dural Venous Sinus Stenting
Description: See Dural Venous Sinus Stenting arm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cerebrospinal Fluid Shunting
Description: See Cerebrospinal Fluid Shunting arm.
Study: NCT02862418

Intervention type: OTHER
Intervention: UTE MRI
Description: One MRI with UTE settings will be acquired.

Intervention type: OTHER
Intervention: UTE MRI
Description: One MRI with UTE settings will be acquired.
Study: NCT03480971

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tempol
Description: Investigational product is Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl) oral solution. Tempol solution is an orange-colored, aqueous solution containing 7% Tempol along with xanthan gum, xylitol, aspartame, acesulfame potassium, sodium saccharin, alcohol, peppermint and wintergreen oils.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Solution
Description: The placebo contains the same excipients as the active product plus FD\&C Yellow #6 for color matching.
Study: NCT00112151

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 2.5 gm gel packets applied once daily. Sham adjustments made during the first 12 weeks. Duration is 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HighT
Description: High Dose Testosterone Group applies two 2.5 gm active packets, titrated to a target blood range of 600-1000 pg/ml)during the first 12 weeks. Total exposure duration is 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HighT
Description: High Dose Testosterone Group applies two 2.5 gm active packets, titrated to a target blood range of 600-1000 pg/ml)during the first 12 weeks. Total exposure duration is 52 weeks.
Study: NCT01990599

Intervention type: OTHER
Group type: OTHER
Intervention: Nasopharyngeal Tube
Study: NCT01712386

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot placebo
Study: NCT04497558

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Endometrium biopsy
Description: In the experimental group, those patients undergo endometrial receptivity array. In the control group, those patients do not receive any treatment before next cycle of transfer. In the experimental group, according to the results of endometrial receptivity array, the transplantation time will be adjusted and retransplantation will be carried out. In the control group, no intervention will be performed.
Study: NCT00862212

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Alcohol Intervention
Description: At the Week 6 visit, all subjects who are randomized to the Experimental Group will receive the experimental brief alcohol intervention. The intervention will be in addition to a standard 20-minute physician visit, for a maximum of 30 minutes. The physician will use the Updated NIAAA Clinician's Guide to ask about drinking and will draw the connection between social anxiety and drinking and how they relate to each other. Subjects will be asked to consider making changes in their drinking and if they agree, a goal will be set and progress toward that goal will be monitored at subsequent visits.
Study: NCT00434590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric coated mycophenolate sodium (Myfortic®)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enteric coated mycophenolate sodium (Myfortic®)
Study: NCT01547728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant antithrombin (rhAT)
Description: Subjects will receive an intravenous bolus of 500 units of recombinant, human antithrombin (rhAT, ATRYN ®). If the subject remains heparin-resistant, one more IV bolus of 500 units rhAT is given.
Study: NCT03391466

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Axicabtagene Ciloleucel
Description: A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously following a conditioning chemotherapy regimen of fludarabine and cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders.
Description: Platinum-containing salvage chemotherapy (R-ICE, R-DHAP, R-ESHAP, or R-GDP as selected by treating investigator) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders.
Study: NCT00918398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981
Description: 514 mg oral solution, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981
Description: 500 mg oral tablet A (optimal dissolution) give as 2x250 mg tablets, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981
Description: 500 mg oral tablet B (slower dissolution) give as 2x250 mg tablets, single dose
Study: NCT05181696

Intervention type: DIAGNOSTIC_TEST
Intervention: Chest X-ray
Description: Retrospective analysis of chest x-rays of patients with COVID-19
Study: NCT03391466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously
Study: NCT04498429

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Cueing Protocol
Description: The first 5 repetitions will include part to whole task practice of partial sit to stand using scripted verbal cueing to facilitate understanding of the task. The goal is to improve midline orientation and alignment during the task of moving from sitting to standing. In addition to verbal cueing, the manual cueing group will receive hands-on tactile facilitation from a trained physical therapist to facilitate appropriate midline weight shift during the sit to stand activity for the series of 40 training repetitions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Verbal Cueing Protocol
Description: The first 5 repetitions will include part to whole task practice of partial sit to stand using scripted verbal cueing to facilitate understanding of the task. The goal is to improve midline orientation and alignment during the task of moving from sitting to standing. The verbal cueing protocol consists of verbal cueing from a trained physical therapist to facilitate appropriate midline weight shift during the sit to stand activity for the series of 40 training repetitions.
Study: NCT02039336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Study: NCT03803683

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mLab App
Description: The mLab App is a web application that uses an image processing algorithm to interpret the results of the OraQuick® In-Home HIV Test.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV Prevention Information
Description: Youth randomized to the standard of care will be sent an email with links to mobile-optimized online prevention information, including PrEP and HIV testing information that is found on the Centers for Disease Control and Prevention (CDC) website.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV Prevention Information
Description: Youth randomized to the standard of care will be sent an email with links to mobile-optimized online prevention information, including PrEP and HIV testing information that is found on the Centers for Disease Control and Prevention (CDC) website.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV Prevention Information
Description: Youth randomized to the standard of care will be sent an email with links to mobile-optimized online prevention information, including PrEP and HIV testing information that is found on the Centers for Disease Control and Prevention (CDC) website.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HIV Home Tests
Description: Youth randomized into this arm will receive OraQuick® In-Home HIV Test.
Study: NCT04519138

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endodrill Model X
Description: The investigational device Endodrill Model X is used for biopsy sampling in the upper gastrointestinal tract

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fine-needle aspiration/biopsy
Description: The standard method is used for biopsy sampling in the upper gastrointestinal tract
Study: NCT05982379

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technology Based Motivation Program
Description: A 10-week Technology Based Motivation Program was given to the intervention group. The website and four training modules were used with the children in the intervention group. Nine coaching interviews with each child (once a week) were conducted over WhatsApp. The children were encouraged to do progressive relaxation and breathing exercises at least twice a week, and eight therapeutic stories (once a week) were sent to the child's phone in the form of animation.~Three training modules were used with the primary caregivers, and coaching interviews were conducted on WhatsApp twice during the program. Primary caregivers practiced progressive relaxation and breathing exercises at least twice a week. In addition, eight motivation messages were sent to the child and primary caregiver, and 24/7 consultancy was provided.
Study: NCT01620047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl 3 µg/ml continuously infused for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU)through a femoral nerve sheath catheter.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine 0.1% delivered through a femoral nerve sheath catheter continuously for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: 0.9% normal saline delivered through a femoral nerve sheath catheter in addition to a continuous intravenous infusion of fentanyl 3 µg/ml via a PCA pump for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
Study: NCT03759197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 188-0551 Spray
Description: Topical Spray containing active drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Spray
Description: Topical Spray containing no active drug
Study: NCT04804436

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic analysis
Description: he real-time PCR amplification was performed in a final volume of 20μL reaction mixture, including 10 ng of genomic DNA, 5 µL of TaqMan® Universal PCR Master Mix, and 0.5 µL of 40X TaqMan® assay. Thermal cycling conditions were as follows: initial denaturation at 94℃ for 3 min, 40 cycles of 94℃ for 15 s, and 60°C for 1 min. The Rotor-Gene Q Series Software Version Q 2.3.1 (Rotor-Gene Q Series, Ziagen) was used for allelic discrimination.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic analysis
Description: he real-time PCR amplification was performed in a final volume of 20μL reaction mixture, including 10 ng of genomic DNA, 5 µL of TaqMan® Universal PCR Master Mix, and 0.5 µL of 40X TaqMan® assay. Thermal cycling conditions were as follows: initial denaturation at 94℃ for 3 min, 40 cycles of 94℃ for 15 s, and 60°C for 1 min. The Rotor-Gene Q Series Software Version Q 2.3.1 (Rotor-Gene Q Series, Ziagen) was used for allelic discrimination.
Study: NCT01716637

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Curcum.Luteol.Theaflav.Lip.Acid,FishOil,Quercet.,Resveratr.
Study: NCT03803683

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIV Home Tests
Description: Youth randomized into this arm will receive OraQuick® In-Home HIV Test.
Study: NCT01716637

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Curcum.Luteol.Theaflav.Lip.Acid,FishOil,Quercet.,Resveratr.
Study: NCT00538564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tadalafil
Description: 10mg oral tablets taken 3 times a week for 2 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablets taken orally 3 times a week for 2 months
Study: NCT01241084

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Antileukotrienes + Lactobacillus reuteri
Description: Montelukast (5mg/die) + 1000000000 CFU per day (5 drops) for 2 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Antileukotrienes + Placebo
Description: Montelukast (5mg/die) + 5 drops of placebo daily for 2 months
Study: NCT04565353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flu shot text messages
Description: Participants will receive text messages per descriptions listed in the arms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flu shot text messages
Description: Participants will receive text messages per descriptions listed in the arms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flu shot text messages
Description: Participants will receive text messages per descriptions listed in the arms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flu shot text messages
Description: Participants will receive text messages per descriptions listed in the arms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flu shot text messages
Description: Participants will receive text messages per descriptions listed in the arms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flu shot text messages
Description: Participants will receive text messages per descriptions listed in the arms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flu shot text messages
Description: Participants will receive text messages per descriptions listed in the arms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flu shot text messages
Description: Participants will receive text messages per descriptions listed in the arms.
Study: NCT00729924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: 400mg orally every 12 hours for 7 days
Study: NCT01199107

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure
Description: 75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders
Study: NCT04565353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flu shot text messages
Description: Participants will receive text messages per descriptions listed in the arms.
Study: NCT01199107

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure
Description: 75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 30 minutes of moderate-intensity treadmill exercise prior to the Prolonged Exposure

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness Intervention
Description: 30 minutes of wellness education prior to Prolonged Exposure
Study: NCT02643329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF-Gliclazide Tablet 80mg
Description: BF-Gliclazide Tablet is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diamicron 80mg Tablet
Description: Diamicron 80mg Tablet is manufactured by Les Laboratoires Servier Industrie, France
Study: NCT02039336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0325901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study: NCT04565353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flu shot text messages
Description: Participants will receive text messages per descriptions listed in the arms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flu shot text messages
Description: Participants will receive text messages per descriptions listed in the arms.
Study: NCT02544074

Intervention type: BEHAVIORAL
Intervention: eSAGE testing
Description: Neuropsychological testing including the eSAGE tablet and eSAGE smartphone

Intervention type: BEHAVIORAL
Intervention: eSAGE testing
Description: Neuropsychological testing including the eSAGE tablet and eSAGE smartphone

Intervention type: BEHAVIORAL
Intervention: eSAGE testing
Description: Neuropsychological testing including the eSAGE tablet and eSAGE smartphone

Intervention type: BEHAVIORAL
Intervention: eSAGE testing
Description: Neuropsychological testing including the eSAGE tablet and eSAGE smartphone

Intervention type: BEHAVIORAL
Intervention: eSAGE testing
Description: Neuropsychological testing including the eSAGE tablet and eSAGE smartphone

Intervention type: BEHAVIORAL
Intervention: eSAGE testing
Description: Neuropsychological testing including the eSAGE tablet and eSAGE smartphone

Intervention type: BEHAVIORAL
Intervention: eSAGE testing
Description: Neuropsychological testing including the eSAGE tablet and eSAGE smartphone

Intervention type: BEHAVIORAL
Intervention: eSAGE testing
Description: Neuropsychological testing including the eSAGE tablet and eSAGE smartphone

Intervention type: BEHAVIORAL
Intervention: eSAGE testing
Description: Neuropsychological testing including the eSAGE tablet and eSAGE smartphone

Intervention type: BEHAVIORAL
Intervention: eSAGE testing
Description: Neuropsychological testing including the eSAGE tablet and eSAGE smartphone
Study: NCT03293797

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abbreviated-Mindfulness-based Therapy
Description: A-MBT will be delivered in group format, 120 minutes per week, for 5 consecutive weeks with 10-20 participants per group.